TCG again backs Surrozen in $50M series B

Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined.

Surrozen Inc. (South San Francisco, Calif.) raised $33 million in a series A in 2017 led by The Column Group, which has returned for the series B along with undisclosed individual existing investors. New investors include Horizons Ventures, Hartford HealthCare Endowment and NS Investment...